Clinical Trial

Water Vapor Ablation for Grade Group 3 Prostate Cancer

Study acronym: VAPOR 3
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation System ("Vanquish") in participants with Grade Group 3 (GG3) intermediate-risk prostate cancer. Participants will undergo therapy with the Vanquish System and complete follow up visits at 7 days, 6 weeks, 6 months, 12 months, 18 months, and 24 months.
Protocol Amendment History 2 changes
notable Enrollment increased: 50 -> 120 participants 2026-06-30
critical Primary endpoint(s) modified 2026-06-25
Trial Details
NCT Number NCT07652164
Lead Sponsor Francis Medical Inc.
Conditions Prostate Cancer
Enrollment 120 participants
Start Date 2026-08-31
Primary Completion 2028-08 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-11